The US Food and Drug Administration (FDA) has strengthened its warning for canagliflozin (Invokana, Invokamet, Johnson & Johnson/Janssen) related to the increased risk for bone fractures. The "Adverse ...

The new indication is based on results of the CREDENCE trial, which found that canagliflozin reduced the risk of renal failure or death by 30% in those that had both type 2 diabetes and diabetic ...

Rockville, MD - The US Food and Drug Administration (FDA) has approved a novel glucose-lowering agent, canagliflozin (Invokana, Janssen Pharmaceuticals) for the treatment of adults with type 2 ...

Aging-related physiological decline and the accumulation of senescent or aging cells in bodily tissues can trigger a number of diseases. The removal of senescent cells, also known as "senolysis," can ...

Results of the landmark study, the first in a series of renal outcomes studies for SGLT2 inhibitors, will be of great interest to policy makers given the cost of dialysis to Medicare. Canagliflozin, ...

Sodium-glucose co-transporter 2 (SGLT2) inhibitors reduce the risk of cardiovascular and kidney outcomes in patients with type 2 diabetes, but it is unclear whether their effects differ based on ...

Treating heart failure (HF) patients with canagliflozin (Invokana; Janssen), a sodium-glucose cotransporter 2 (SGLT2) inhibitor, significantly improves quality of life, with the marked benefit ...

A 76-year-old Filipina woman who had been taking rosuvastatin 40 mg per day without a problem for more than 5 years started developing pain and weakness in her thighs just days after starting on the ...

Review the side-effects of Canagliflozin as documented in medical literature. The term "side effects" refers to unintended effects that can occur as a result of taking the medication. In majority of ...

Please provide your email address to receive an email when new articles are posted on . The first sodium-glucose cotransporter 2 inhibitor, canagliflozin, recently reached the market. These drugs ...